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Controversies on the endoscopic and 
surgical management of pain in 
patients with chronic pancreatitis: pros 
and cons!
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Lars Arendt-Nielsen,4 Marc G Besselink,2 Marja A Boermeester,2 
Stefan Bouwense,5 Marco Bruno,6 Martin Freeman,7 Thomas M Gress,8 
Jeanin E van Hooft,9 Bart Morlion,10 Søren Schou Olesen,   1 
Hjalmar van Santvoort,11,12 Vikesh Singh,13 John Windsor14
IntroduCtIon
Pain is the dominating symptom of 
chronic pancreatitis (CP) causing impair-
ment of quality of life, decreased activity, 
unemployment and major healthcare 
costs.1 Opinions differ on the best strategy 
to treat CP-related pain. These differences 
are fuelled by the lack of a clear correla-
tion between the severity of complaints 
and the presence and extent of morpho-
logical abnormalities, lack of a compre-
hensive pain assessment tools, deficiency 
in the knowledge about the natural course 
of CP and the presence of (changes in) 
both peripheral and central nervous 
system pain mechanisms.
Analgesics are the cornerstone of 
pancreatic pain management, but when 
opioids are used, it may lead to depen-
dency and opioid-induced hyperalgesia.2 
When analgesic therapy fails, invasive 
treatments including endoscopic pancre-
atic duct clearance (with or without extra-
corporeal shock wave lithotripsy (ESWL)) 
or pancreatic duct stenting and surgery 
(resection and/or ductal decompression) 
are used. The rationale for invasive treat-
ments is that reducing ductal pressure 
by restoring pancreatic juice flow and/or 
resecting an inflammatory pancreatic mass 
will result in pain relief. However, there is 
also a neuropathic basis for pain in most 
patients, for which invasive treatments 
may not be effective or even harmful. 
While there are many clinical studies 
that support invasive treatments, there 
is a paucity of high-quality randomised 
controlled trials (RCTs). As a result, the 
current guidelines for endoscopic and 
surgical treatments for painful CP are 
inconsistent and tend to reflect a specialty 
bias.3 For example, the German guidelines4 
recommend surgery as the most effective 
treatment of pain, whereas the European 
Society of Gastrointestinal Endoscopy5 
and the international evidence-based 
(HaPanEU) guidelines1 advice a ‘step-up 
approach’ incorporating both conserva-
tive, endoscopic and surgical treatment. 
These contradictions allow historic bias 
and a significant variation in clinical prac-
tice. Gut received a review article on the 
treatment of pain in CP that challenged 
current guideline recommendations and 
initiated a lively and exciting debate 
between authors and reviewers, which the 
editors of Gut wanted to share with their 
readers. For this purpose, a novel article 
format was designed, which would allow 
both sides (‘pros' and 'cons’) to present 
and discuss their views on the clinical 
and experimental studies that provide the 
evidence for invasive treatment of pain in 
patients with CP, to identify the knowledge 
gaps and to define what is required for the 
conduct of future studies, and to debate 
the pros and cons. To address these aims, 
this article is authored by opinion leaders 
in favour (MAK, SAWB, JEvH, HCvS, 
DKA, MLF, JAW, MJB, MAB, MGB) and 
against (AMD, SSO, BM, LA-N, VKS) the 
current interventional treatment recom-
mendations and moderated by the asso-
ciate editor of Gut for pancreatic diseases 
(TMG).
the Cons of InterventIonal 
treatment of paIn In ChronIC 
panCreatItIs
pathophysiology of pain contradicts the 
rationale for invasive treatment
For many years, the theoretical framework 
for the invasive treatment of patients with 
painful CP has been that the pain is gener-
ated by localised pathology, namely focal 
pancreatic duct obstruction and/or local-
ised inflammatory mass. This framework 
is challenged by the inability to demon-
strate any relationship between pancreatic 
morphology and pain6 7 or postoperative 
pain relief.8–10 This lack of correlation 
between morphology and pain is not 
unique to CP, but is also evident in patients 
with endometriosis, osteoarthritis, neuro-
pathic pain and peptic ulcer.11 Therefore, 
invasive treatments (surgery or endos-
copy) directed to overcome partial or 
complete pancreatic duct obstruction (the 
‘plumbing theory’ in figure 1), including 
endoscopic stenting, endoscopic stone 
removal and decompressive pancrea-
to-jejunostomy,12–14 may not be justified 
for many patients. Further, a substantial 
proportion of patients with typical pancre-
atic pain do not have major morphological 
changes (eg, ‘minimal change’ and ‘small 
duct’ CP) that are amenable to surgical or 
endoscopic treatment.
Neuroablative procedures including 
endoscopic celiac plexus blockade, 
surgical splanchnicectomy and even total 
pancreatectomy target neuropathic pain 
(the ‘wiring theory’ in figure 1), but suffer 
from the same fundamental problems 
as the aforementioned decompression 
procedures. It is known that neuropathy, 
as defined by the International Associa-
tion for the Study of Pain, plays a major 
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role in painful CP,15 and the severity of 
neuropathy is correlated with pain inten-
sity.16 Neuropathic changes have been 
discovered at all levels of the nervous 
system (figure 1).17–19 Sensitisation of 
central nociceptive pathways is acceler-
ated by acute disease flares and painful 
comorbid conditions.18 Hence, continued 
nociceptive input on central pathways 
may ultimately result in an autonomous 
and self-perpetuating pain state, which is 
independent of the peripheral nocicep-
tive drive.11 When this state develops, it 
is unlikely that any local neuroablative 
procedure will be effective.19 In support, 
generalised hyperalgesia in patients with 
painful CP, as objectively measured with 
quantitative sensory testing (QST), was 
associated with failure of thoracoscopic 
splanchnic denervation.20
The argument for invasive treatments 
of neuropathic pain is that removal of 
the source of nociceptive pain (eg, by 
pancreatic resection) would decrease the 
barrage from primary afferents and, over 
time this would reduce pain severity. 
Similarly, the argument for neuroablative 
procedures is that this would decrease 
primary afferent activity and therefore 
pain severity. This has some credence 
as neural blocks and local analgesics 
can be effective for peripheral nerve 
injury and painful polyneuropathy.21–24 
However, while medical treatment aims 
to reduce the membrane potentials and 
firing thresholds of pathological neural 
circuits, there is evidence that neuroab-
lative procedures (after initial alleviation 
of pain) can promote spontaneous firing 
of peripheral afferents due to disinhibi-
tion and upregulation of ion channels. 
This can lead to a cascade of central 
nervous system events followed by sensi-
tisation and worsening of pain.25 Hence, 
procedures based on neural destruc-
tion may promote development of new 
neuropathic pain, formerly known as 
‘deafferentation pain’.18 Taken together, 
these mechanisms may explain the 
reduced long-term efficacy of invasive 
treatments.26
What can surgeons learn from invasive 
treatments in other painful conditions?
For lack of other options, surgeons have 
historically attempted to excise chronic 
pain. Although not studied after pancreas 
surgery, consequences after nerve damage 
are dependent on procedure rather than 
disease, and therefore, the experience 
from invasive treatment in other diseases 
is valid in this context. Destructive, 
irreversible neurolytic procedures have 
included cauterisation of the sciatic 
nerve for sciatica, amputations for limb 
pain, dorsal root entry zone rhizotomies 
and resection of neuromas for phantom 
limb pain.27 Such approaches have failed 
and the lack of controlled clinical data 
has meant that these techniques have 
become historical anecdotes.28 Despite 
this, the continuing support for pancre-
atic resection for chronic pain persists in 
the treatment of CP and has been given 
further impetus with popularisation of 
total pancreatectomy with islet auto 
transplantation (TPIAT), including resec-
tion even before the onset of pain.
Some surgical treatments for chronic 
pain can be considered neuroablative. 
A common example is microdiscectomy 
for the management of radicular pain. 
Although many patients with sciatica 
report pain relief in the first 3 months, 
most still had mild to moderate symp-
toms 5 years after surgery.29 Another 
figure 1 Schematic overview of the pathophysiology of pain in chronic pancreatitis, for details see Olesen et al.19 (A) Mechanical obstruction of the 
pancreatic duct system and/or increased intra-glandular pressure (the ‘plumbing’ theory), as well as local inflammatory masses. (B) Peripheral nerve 
damage with ectopic activity resulting in stimulus-dependent and spontaneous pain (the ‘wiring’ theory). (C) (insert): (1) Sprouting of non-nociceptive 
nerve afferents normally responsible for non-painful sensations into 'pain-specific’ areas of the spinal cord resulting in allodynia (pain to stimuli that 
are normally not painful); (2) sprouting of sympathetic neurons into the dorsal horn neurons rendering the system sensitive to sympathetic activity 
and catecholamine; (3) sensitisation and phenotypic changes of spinal neurons due to increased afferent barrage; (4) abnormal coding of the afferent 
input from other viscera (and somatic structures) resulting in increased referred pain and viscero-visceral hyperalgesia; (5) local disinhibition by 
interneurons that normally controls pain intensity. (D) Reorganisation and structural changes in the brain that encodes complex sensations such as 
affective, evaluative and cognitive responses to pain. (E) Defects in descending pathways arising in the brain stem that normally inhibit the peripheral 
afferent activity at the spinal cord level.
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example of this is revisional surgery 
after total knee arthroplasty, where 85% 
of revision patients have more intense 
pain and sensitisation compared with 
their baseline levels.30 31 More recently, 
neuromodulation has been developed 
as a less invasive treatment option, 
including spinal cord stimulation and 
targeted intrathecal pharmacotherapy 
(eg, morphine pump).32 While these are 
considered relatively safe and produce 
significant pain reduction, there is a lack 
of randomised placebo-controlled trials 
to support it.33 34
flaws in studies of invasive treatments 
for painful chronic pancreatitis
Treatment by endoscopy and/or surgery 
are commonly offered as part of a 
step-up approach, when lifestyle changes 
and drug treatment fails.2 35 Many obser-
vational studies or studies comparing 
different procedures have reported 
benefits from endoscopic and surgical 
treatment of CP pain.36 However, these 
symptomatic benefits are time depen-
dent, and it is common for relapse to 
occur over time.26 37–39 This relapse may 
be due to progression of the neuropathy, 
development of further duct strictures 
and/or fibroinflammatory processes, as 
well as the loss of the placebo effect of 
intervention.40
Studies related to neuroablative proce-
dures are often biased by patient selec-
tion, have failed to control for differing 
aetiologies and definitions of CP, have 
a short follow-up period, and/or use 
poor pain assessment methodology.40 
For example, celiac plexus neurolysis 
improves analgesia and decreases opioid 
consumption in patients with pancreas 
cancer,32 but benefits are time limited 
(about 3 months). As the nerve damage 
may even worsen the neuropathic mech-
anisms as outlined above, it should be 
considered obsolete in patients with 
painful CP.2 41 42 TPIAT involves dener-
vation and is becoming increasingly 
available. Although open studies have 
shown that both total pancreatectomy 
(alone) and TPIAT can reduce pain, there 
are significant issues with risk, cost and 
consequences of such an invasive treat-
ment. Some of the benefits may derive 
from better monitoring and control of 
diabetes and greater attention to nutri-
tional management. Additionally, a crit-
ical follow-up study has showed that 
most TPIAT patients develop functional 
pain and other pain syndromes,43 and 
caution is advised to promote this treat-
ment outside protocolled studies.
sham-controlled studies are mandatory 
to confirm the effect of invasive 
treatments
The well-known placebo effect has also 
been investigated in pharmacological pain 
management of CP. The effect size is about 
20%,44 and this is similar to what has 
been found in studies with analgesics for 
other conditions, including painful gastro-
intestinal diseases.45 46 As no placebo/
sham-controlled trials of invasive thera-
pies for painful CP exist, previous studies 
may be subject to selection bias and the 
effects on pain per se are still unanswered 
(figure 2). Due to lack of studies in CP, 
it is worthwhile to consider the effect of 
sham-controlled surgical trials for other 
painful conditions. Examples include lapa-
roscopic adhesiolysis for abdominal pain, 
arthroscopic meniscectomy for knee pain, 
subacromial decompression for shoulder 
pain, percutaneous coronary intervention 
for angina and vertebroplasty for painful 
vertebral compression fractures.47–53 
Although these procedures are well estab-
lished and the indication for pain has not 
been questioned (with results similar to 
surgery for CP (table 1)), all the studies 
demonstrated no difference in pain inten-
sity between active treatment and sham. 
This was confirmed in meta-analyses of 
invasive procedures for painful conditions 
(other than CP), where improvements in 
the sham arm was seen in up to 75%.54–56 
Another more recent meta-analysis 
confirmed that the effect of sham surgery 
on pain was about 40%, with studies 
reporting up to 60% pain improvement.56 
More specifically for pancreatology, 
Cotton et al randomised 214 patients 
with sphincter of Oddi dysfunction to 
sphincterotomy or sham.57 There was 
reduction in pain in both groups, but the 
sham treatment performed significantly 
better. Later, the authors reported that 
the 47% of the sham-treated patients had 
>50% reduction in pain and 37% had no 
pain at all.58 This study has questioned the 
use of invasive treatments in patients with 
pancreatogenic pain. It is worth noting 
that the effect size of sham treatment in 
these studies is of a similar magnitude to 
that seen in studies investigating endo-
scopic and surgical treatment for painful 
CP (table 1). Unfortunately, the ethical 
challenges of conducting sham-controlled 
studies in surgery (open or laparoscopic) in 
CP are well recognised,59 but in contrast, 
it is possible to conduct sham-controlled 
endoscopic treatments.3
the pros of InterventIonal 
treatment of paIn In ChronIC 
panCreatItIs
In the recent international evidence-based 
(HaPanEU) guidelines, a multidisciplinary 
step-up approach for the treatment of 
pain in CP was recommended,1 although 
specific trials investigating this approach 
are yet to be performed. The first step is 
conservative therapy, including lifestyle 
management (eg, cessation of alcohol use 
and smoking), dietary advice and pain 
medication. The approach to pain manage-
ment of the WHO is widely accepted for 
pain treatment in CP, although it has not 
been formally evaluated.60 If patients 
have persistent pain despite appropriate 
conservative measures, including opti-
misation of pain medication, subsequent 
interventional endoscopy or surgery is 
figure 2 A hypothetical illustration of the pain intensity over time (solid curve) in a patient 
with chronic pancreatitis. At the initial course of disease, the pain is fluctuating and may reach 
a high intensity as illustrated on the y-axis. When pain intensity is the highest, the patient may 
be desperate and seek invasive treatment (arrow). However, the natural course of disease (in 
this case, the pain temporarily improves) is not taken into consideration when the outcome of 
uncontrolled studies of invasive treatment is evaluated. Such a selection bias necessitates a 
control group subjected to sham surgery/endoscopy before any definitive conclusions regarding 
effectiveness of treatment can be taken. The placebo effect (stippled green line) can further add to 
the pain relief after invasive treatments.
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recommended. While endoscopy is often 
used as the first approach in patients with 
solitary strictures and single pancreatic 
duct stones in the head of the pancreas, 
there are also indications for surgery as 
the first intervention, such as an inflam-
matory head mass in which cancer cannot 
be excluded. There is a large literature, 
both non-randomised and randomised, 
supporting the efficacy of interventional 
endoscopy and surgery in the treatment of 
symptomatic CP.13 26 61
Interventions in chronic pancreatitis: 
what we know
Medical therapy
Around 50% of patients with CP require 
pain medication on a daily basis, and the 
vast majority take opioids, despite the lack 
of evidence that they are effective for long-
term pain management.62 63 Further, the 
longer patients are treated with opioids, 
the greater is the risk of opioid depen-
dence and side effects such as opioid-in-
duced constipation, cognitive dysfunction 
and hyperalgesia.1 64 65 As a result, there is 
acceptance that the lowest effective dose 
of opioids should be used.
Patients with long-standing CP can 
develop changes in the central nervous 
system leading to pain that is less depen-
dent on peripheral driving factors (noci-
ception from local inflammation of the 
pancreas).66 To treat this ‘central sensi-
tisation’ and reduce the effective opioid 
dose, neuropathic pain medication (eg, 
gabapentin or amitriptyline) is widely used 
in clinical practice in conjunction with 
other analgesics and interventional treat-
ment in CP. Only one trial investigated this 
strategy in the short term (see table 1), and 
long-term efficacy is unknown.67 What 
is important to note, especially in the 
absence of compelling evidence, is that all 
analgesic strategies are adjunctive because 
they do not specifically target the drivers 
of painful CP.
All patients requiring opioid analgesia 
for CP should be discussed at a multidis-
ciplinary meeting to determine whether 
they should be referred for interventional 
endoscopy or surgery.1 A large proportion 
of these patients will have morphological 
abnormalities such as a ductal obstruction 
with upstream dilatation due to ductal 
strictures, ductal stones, inflammatory 
pancreatic (head) mass and/or pseudo-
cysts.12 68 69 Although the correlation 
between pain and the presence and extent 
of morphological abnormalities is highly 
variable, several RCTs have confirmed 
pain relief attributable to the interven-
tions in the majority of these patients, see 
table 1.1 2
Interventional endoscopy
There are a number of morphological 
abnormalities that can be treated by inter-
ventional endoscopy on the premise that 
the intervention reduces pancreatic duct 
obstruction and hypertension. These inter-
ventions include pancreatic and biliary 
stricture dilation/stenting, pancreatic duct 
stone removal and drainage of pseudo-
cysts.70 Several observational cohort 
studies have reported a long-term pain 
relief in substantial proportions of patients 
following interventional endoscopy. Two 
studies of 57 and 1018 patients reported 
pain relief in >60% of the patients after 
1 and 5 years, respectively.12 71 In patients 
with large intraductal stones (>5 mm), 
ESWL and subsequent endoscopic stone 
extraction can be effective.1 70 There is one 
RCT in which ESWL with and without 
subsequent endoscopic stone extraction 
was compared in 55 patients. After 
2 years, the pain relief was comparable 
between both groups (55% vs 62%).72 See 
table 1 for a structured overview of studies 
mentioned above.
Surgery
Surgery is effective both in patients with 
a ductal obstruction and an inflamma-
tory head mass. The most commonly 
performed procedure is pancreatic duct 
drainage by a lateral pancreaticojeju-
nostomy, in which the pancreatic duct is 
opened along its entire length and anas-
tomosed (side to side) to a Roux-Y jejunal 
limb.73 An inflammatory head mass can be 
resected using pancreatoduodenectomy 
or a duodenum preserving pancreatic 
head resection such as the Berne, or Beger 
procedures.74 75 Ductal drainage and 
duodenum preserving (partial) head resec-
tion are combined in a Frey procedure.76 
Surgery is reported to have a good long-
term effect although approximately 10% 
of patients will not respond, and this risk 
is higher in patients who have had a large 
number of endoscopic procedures prior to 
surgery.77
Two RCTs have compared endoscopic 
and surgical management in patients with 
painful obstructive CP.13 61 Both studies 
showed superiority of surgical over endo-
scopic management. The study of Dite 
et al randomised 72 patients with CP 
and reported, after 5 years of follow-up, 
34% complete and 52% with partial relief 
after surgery, versus 15% had complete 
pain absence and 46% partial relief after 
endoscopy. However, endoscopy in this 
study was not optimal since no ESWL 
was applied.61 The study by Cahen et 
al randomised 39 patients with painful 
obstructive CP and reported, after 2 years 
table 1 Highlights of studies on pain treatment in chronic pancreatitis
study design n Interventions follow-up pain relief (%)*
Endoscopy
Rosch et al12 Cohort 1018 Endoscopy (including ESWL) 4.9 years† 65
Tadenuma et al71 Cohort 57 Endoscopy (including ESWL) 1 year 63
Dumonceau et al72 RCT 55 ESWL with/without subsequent endoscopy 2 years 55 vs 62 (p=0.651)
Conventional surgery
Dite et al61
  
RCT 72 Endoscopy (without ESWL) versus surgery 5 years 61 vs 86 (p=0.002)
Cahen et al13 RCT 39 Endoscopy (including ESWL) versus surgery 2 years 32 vs 75 (p=0.007)
Cahen et al26 Long-term results RCT 31 Endoscopy (including ESWL) versus surgery >6 years 38 vs 80 (p=0.042)
TPIAT
Bellin et al82 Cohort 215 TPIAT 10 years 82
Neuropathic pain medication
Olesen et al67 RCT 64 Pregabalin versus placebo 3 weeks 36 vs 24 (p=0.02)
*Complete and partial pain relief combined.
†Mean.
CP, chronic pancreatitis; ESWL, extracorporeal shockwave lithotripsy; RCT,  randomised controlled trial; TPIAT, total pancreatectomy with islet autotransplantation.
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of follow-up, 75% pain relief after surgery 
versus 32% after endoscopy, which 
included ESWL (p=0.007).13 In long-
term follow-up, these results remained 
stable after >6 years, with 80% pain relief 
in the surgery group versus 38% pain in 
the endoscopy group.26 Complete pain 
relief was seen in 53% of patients after 
surgery versus 25% after endoscopy.26 
It was also noted that 47% (9/16) of the 
endoscopic-treated patients required 
delayed surgery, and complete pain relief 
was found in only 2/9 (22%) patients with 
delayed surgery compared with the 8/15 
(53%) who had primary surgery. Several 
RCTs that compared different surgical 
strategies for CP have reported long-term 
pain relief of around 80% after 7–15 years 
follow-up.39 78 79 The most recent inter-
national RCT compared duodenum-pre-
serving pancreatic head resection with 
pancreatoduodenectomy in 250 patients 
with CP and an inflammatory pancreatic 
head mass. Two years after surgery, pain 
scores and the mean quality of life signifi-
cantly improved in both groups, without 
significant differences.80
An evolution in the surgical intervention 
for CP is TPIAT, first reported in 1977. 
As conventional surgery and endoscopic 
treatment may not be feasible or successful 
in up to 50% of patients, TPIAT is based 
on the concept of complete removal of 
the source of pain while maintaining islet 
cell function to avoid or mitigate the risk 
of diabetes by infusing the patient’s own 
islet cells into the portal circulation to 
engraft within the liver.81 Application of 
TPIAT is growing worldwide and it might 
be considered appropriate for paedi-
atric patients, those without pre-existing 
diabetes, those with hereditary pancre-
atitis and those with small duct disease 
for whom decompression is not possible. 
A single-centre observational study has 
reported on 215/742 TPIAT patients with 
at least a 10-year follow-up. Complete and 
sustained pain relief was present in 82% at 
10 years and 90% at 15 years, with either 
full or partial islet graft function in nearly 
50% patients.82
Based on the available evidence, both 
surgery and endoscopy are durable (and 
not time dependent as suggested by the 
con group), although surgery provides 
the superior outcome (table 1). There 
are some patients who will benefit from 
an endoscopy-first approach, including 
those with (single) pancreatic duct stones 
or strictures confined to the head of 
the pancreas in whom complete ductal 
clearance can be achieved. While this is 
a reasonable approach, there is a risk of 
delay in referral for surgery when the 
outcome of endoscopy proves unsatis-
factory. An increasing body of evidence 
suggests that earlier surgical intervention 
leads to better pain control.83–85 After the 
onset of pain, a (long) delay before inva-
sive treatment increases the risk of opioid 
dependence and may lead to sensitisation 
of central pain pathways and changes 
in pain perception, which increases the 
chance of treatment failure.86 On this 
basis, the CON group actually favour 
earlier intervention in painful, obstructive 
CP.
Interventions in chronic pancreatitis: 
what we do not know
Timing of intervention
In current clinical guidelines, there is 
inconsistency regarding the timing and 
whether endoscopy or surgery should 
be offered as the first intervention for 
patients with painful obstructive CP.1 2 70 
There is increasing evidence that suggests 
that earlier surgery leads to better pain 
relief rather than the unproven step-up 
approach, in which medication and 
then endoscopy are offered first.83–85 
It is known that delay in intervention, 
prolonged and repeated episodes of pain 
and opioid dependency are associated 
with the development of neuropathic 
pain.64 87 To resolve this longstanding 
debate about the timing of interven-
tion, the Dutch Pancreatitis Study Group 
conducted the ESCAPE trial.88 Patients 
with painful obstructive CP and a dilated 
pancreatic duct in a very early phase of 
treatment, with a maximum of 2 months 
of opioid use and no prior interven-
tions, were eligible. These patients were 
randomised to either surgical treatment 
within 6 weeks or an optimised current 
step-up approach including endoscopic 
treatment. Primary outcome was pain 
as assessed by the Izbicki pain score, 
a validated pain score specific for CP 
and widely used.13 89 90 The prelimi-
nary results of the ESCAPE trial were 
presented at United European Gastroen-
terology Week 2018 but final results are 
still awaited.
Sham-controlled trials: good in theory, 
problematic in practice
Although all endoscopic and surgical 
intervention trials in CP have shown 
pain relief in a clinically relevant propor-
tion of patients, none of them used sham 
interventions. Trials with a sham inter-
vention as comparator can estimate the 
placebo effect of an intervention, some-
thing of particular interest with studies 
of pain treatment. There is indeed 
evidence that the placebo effect can 
account for up to 65% of the treatment 
effect for invasive procedures, especially 
when treating pain.55 Sham-controlled 
studies, however, are subject to debate 
for both ethical and practical reasons.91 
A sham intervention might be considered 
as dishonest in clinical practice, whereas 
it is a legitimate aspect of research 
design.92 There is an inherent difficulty 
in incorporating a blinded sham-control 
arm in surgical procedures, although this 
can be done more easily in endoscopic 
studies.54 It is also difficult for clinicians 
to deny treatment that they consider 
effective and when not convinced that 
equipoise exists, even in the context of 
an RCT, such as trial requires long-term 
follow-up, and many would consider it 
unethical to deny potentially effective 
treatment for years. Lastly, the effect 
size of endoscopic and surgical treatment 
is such that it seems highly improbable 
that this could be accounted for by a 
sham intervention alone. Is it ethical to 
withhold patients from other treatment 
options for such a prolonged period, 
even if these other options have been 
shown to be successful without sham 
comparison?
faCtors that InfluenCe the 
outCome from InvasIve 
treatment: reCommendatIons for 
future trIals
Advances in the treatment of patients 
with painful CP will require an improved 
study design that takes into account the 
many risk factors that influence outcome 
(table 2). Studies have shown that demo-
graphic variables and imaging features 
are important in the outcomes from 
surgery.8 10 85 93 94 Alcohol and smoking 
also influences outcomes, and alcohol 
abstinence can improve the effect of 
surgery.9 Compared with hereditary or 
idiopathic CP, patients with toxic aetiolo-
gies have improved outcomes from resec-
tional or decompressive procedures,10 but 
worse after TPIAT.93 95 96 This implies that 
the aetiology of CP is a more important 
factor than any morphological changes 
of the pancreas, and future trials should 
more carefully consider the effect of 
smoking and drinking continuance/cessa-
tion. Other factors including depression, 
widespread pain, expectations, catastro-
phizing and sleep deprivation may also 
be important although less well studied in 
CP.2 97 Age also influences outcome with a 
greater efficacy from TPIAT in children as 
discussed below.
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Pain evolution has a significant impact 
on the outcomes from invasive treatment. 
Observational studies of surgical and 
endoscopic therapy have shown improved 
outcomes when performed during the 
early phase of CP,98 especially prior to the 
onset of narcotic dependence and central 
sensitisation.14 26 83–85 99–102 The previously 
mentioned ESCAPE trial may provide data 
on this factor.
Pain pattern is another important 
factor to consider. CP patients with 
constant pain pattern often have a worse 
quality of life, more lost work days, 
increased number of hospitalisations, 
higher pain intensity and more night 
pain.62 103 Constant pain was also associ-
ated with higher levels of exocrine insuf-
ficiency and malnutrition.104 105 Finally, 
constant pain is a predictor of failed 
surgical treatment for painful CP.106 
On the other hand, intermittent pain 
associated with recurrent acute pancre-
atitis is a positive predictor in patients 
having TPIAT.43 Correspondingly, 
TPIAT is more effective in the paedi-
atric CP patients,107 108 which might be 
explained by an immature pain system 
that is less likely to undergo the irrevers-
ible neuroplastic changes observed in 
adult patients. The effect of pain pattern 
is supported by studies in patients with 
other painful neuropathic conditions, 
where a constant pain pattern was also 
associated with a worse outcome from 
treatment.109
Opioid use is associated with more 
hospitalisations,105 and is a predictor of 
failure from surgical treatment.83 Opioids 
can interfere with pain processing, and 
in some instances, contribute to hyperal-
gesia.110 In an individual patient, it is diffi-
cult to determine whether opioids worsen 
the response to treatment. Patients with 
opioid dependence are generally those 
with more severe pain and lower quality 
of life, and as such are more likely to be 
refractory to treatment.
Subjective pain assessment is highly 
variable and the instruments are poorly 
validated.111 Yet, this is the primary indica-
tion for the treatment of patients with CP 
and the most important endpoint of trials. 
The ‘IMMPACT guidelines’ recommend 
that patient factors, study design, study 
site factors and outcome measurements 
are all used in pain evaluation,112 113 and 
patient-reported characteristics should 
also be used in assessing the response to 
invasive treatments.2 111 As most inva-
sive treatment studies have used only 
simple pain assessment instruments, it 
is mandatory to use better validated and 
more comprehensive measures in future 
trials.103 114 115
Objective pain assessment includes 
QST11 and can be combined with subjective 
pain assessment, neurophysiological and 
imaging methods.19 Visceral QST has been 
used in the evaluation of many pain condi-
tions11 but the invasiveness has limited its 
use in clinical practice. Visceral QST has 
also been used in CP to explore different 
pain mechanisms.19 A bedside solution 
that assesses somatic pain sensitivity as 
a proxy for the changes in the central 
nervous system caused by CP has recently 
been developed and validated.116 117 This 
has been shown to reflect disease severity 
and to predict the outcome of medical and 
surgical treatment for painful CP.66 116–119 
However, further studies, including 
normative reference data and additional 
validation in CP patients without pain, are 
required before this approach can be used 
in clinical practice.
ConClusIon
Pain is the predominant and most inca-
pacitating symptom of CP, and current 
guidelines recommend treatment by a 
step-up approach comprising an initial 
pain medication, followed by interven-
tions including endoscopy and surgery. 
However, as highlighted in this debate 
article, the conceptual basis for these 
interventions (ie, reducing pressure in 
pancreatic duct, removing ductal stones 
and resecting inflammatory masses to 
remove local nociceptive source) does 
not take into account the advances in our 
understanding of pain mechanisms, and in 
particular, the importance of neuropathy 
and neuroplastic changes in the central 
nervous system. Furthermore, there 
is a paucity of data from prospective, 
randomised and adequately controlled 
clinical trials as basis for the current inter-
ventional treatment recommendations. 
Although showing that interventions 
improve pain in CP, most randomised 
trials compare different types of interven-
tions or the timing of interventions, rather 
than questioning the indication for inter-
ventions to treat pain in CP, an assump-
tion that may indeed be challenged, as 
described by the ‘con-authors’ in this 
debate. Furthermore, many trials do not 
take into account that CP is heterogeneous 
in many factors such as aetiology, stage, 
duration and pre-treatments, and thus 
different patients may require different 
treatment approaches, making a point for 
the personalisation of algorithms for the 
treatment of pain in CP. To make prog-
ress towards a better understanding of the 
benefits of invasive treatments in CP, it is 
necessary to conduct studies with appro-
priate control arms wherever possible. 
table 2 Factors to be considered in the design of future trials of the endoscopic and surgical treatment of pain in chronic pancreatitis
factors Comments
Demography Variables including age, sex and recurrent acute pancreatitis may influence outcome
Aetiology Toxic aetiology (alcohol and smoking) predicts a better outcome on pain after surgical resection, although the opposite was found after TPIAT
Imaging features Parenchymal calcifications have predicted postoperative pain relief in some studies. Patients with strictures and stones in the main pancreatic duct may 
respond to invasive therapies, but as pathology of the pancreatic duct system is not associated with clinical pain, responders need to be identified
Procedures Multiple endoscopic procedures may negatively affect outcome
Opioid use Opioid use has a negative effect on outcome, but represents a bias as the patients typically represent a subgroup with more severe pain, disability and 
reduced quality of life that predicts a bad outcome to treatment per se
Pain evolution Long pain duration may affect the outcome in a negative way, but data are subject to selection and recall bias. A temporal association between the 
development of pancreatic morphological changes and pain may predict a favourable prognosis to invasive treatments
Pain descriptors Intermittent pain pattern, as opposed to constant pain, may be associated with better outcomes and probably reflects the absence of central 
sensitisation
Pain assessment Validated tools for assessment of the multidimensional pain experience, including assessment of physical, psychological and social functioning, are 
recommended. Catastrophizing and psychological comorbidity to pain also need to be considered. QST may prove useful for objective assessment of pain 
mechanisms, but requires more validation
Design Adequately powered studies, well-defined patient cohorts and randomisation are essential. However, without sham-controlled studies, it is not possible 
to determine non-placebo effect sizes of treatment.
 QST, Quantitative sensory testing; TPIAT,  total pancreatectomy with islet autotransplantation. 
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Additionally, further trials should take 
a more comprehensive and validated 
approach to pain assessment, taking into 
account the many factors that influence 
pain and the efficacy of treatment, espe-
cially the development of central sensi-
tisation. Future RCTs should involve all 
required disciplines such as pain special-
ists, pancreatologists, interventional 
endoscopists and pancreatic surgeons to 
ensure an appropriate design and a wide-
spread acceptance of the results.
Overall, this debate shows that there is 
an urgent need for well-designed, prospec-
tive RCTs in this field of research. Gut 
hopes that this debate article has contrib-
uted to summarise the current evidence 
and the controversies in the treatment 
of pain in CP, and will foster future 
research.
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